Figure1 (Figure1)
Clopidogrel Bisulfate
Product Images NDC 68151-3118
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Clopidogrel Bisulfate (NDC 68151-3118). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Carilion Materials Management, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Figure2 (Figure2)
This is a chart comparing the cumulative event rate for patients taking placebo with aspirin versus clopidogrel with aspirin after several months of follow-up. Other standard therapies were also used as needed. The purpose and nature of the events recorded are not available.*
Figure3 (Figure3)
This appears to be a table depicting different types of events and their percentage in different treatments or groups, possibly related to medical treatments. The table includes information such as the total number of events, the percentage of events, and the specific group or treatment associated with them. There also seems to be a disclaimer or note at the end stating that other standard therapies were used as appropriate.*
Figure4 (Figure4)
This appears to be a medical study report that compares the effects of placebo and clopidogrel on reducing the risk of death. According to the results shared, clopidogrel was associated with a 7% proportional risk reduction in comparison to placebo. The study followed patients for up to 28 days and the number of deaths reported for each group is shared.*
Figure5 (Figure5)
The given text appears to be data from a study on the effectiveness of a drug called Clopidogrel in reducing the risk of death, reinfarction (recurrence of heart attack), or stroke in patients before their first discharge. The study involved two groups - one that was administered Clopidogrel and the other given a placebo. The data shows that out of the 2310 patients who were given a placebo, 10.1% experienced an event (death, reinfarction, or stroke) whereas out of the 2121 patients who were administered Clopidogrel, only 9.2% experienced an event. This suggests that there was a 9% proportional risk reduction in the group that received Clopidogrel. The study also measured the number of days since randomization up to 28 days.*
Figure6 (Figure6)
Figure7 (Figure7)
Figure8 (Figure8)
Label Image (Lbl681513118)
This is a medication called Clopidogrel, which comes in tablet form with a dosage strength of 75 milligrams. The manufacturer of the drug is Sun Pharma and the lot number is JKM6120A. The product's expiration date is August 2014, and there is a code printed on the tablet as W0225143m2.*
Structure (Structure)
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
